Orion OyjORINF +4.81%97 3-Year ROIIC % is 25.45 as of Dec. 2025, which is 252% above its 10-year median of 7.22. GuruFocus rates ORINF with a GF Score™ of 97/100 and a GF Value™ of $80.88. The stock has 3 warning signs investors should review. Among 944 Drug Manufacturers companies, Orion Oyj ranks better than 74.26% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Orion Oyj's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 25.45%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Orion Oyj's 3-Year ROIIC % or its related term are showing as below:
ORINF's 3-Year ROIIC % is ranked better than 74.26% of 944
companies
in the Drug Manufacturers industry
Industry Median: 3.72
vs ORINF: 25.45
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Orion Oyj 3-Year ROIIC % Related Terms
Orion Oyj 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Orion Oyj's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ORINF vs LLY, JNJ, ABBV: 3-Year ROIIC % Comparison
For the Drug Manufacturers - General subindustry, Orion Oyj's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Oyj 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orion Oyj's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Orion Oyj's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Orion Oyj (ORINF) has a 3-Year ROIIC % of 25.45 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Orion Oyj and its competitors. This is 252% above median its historical median of 7.22. According to the industry distribution chart, Orion Oyj ranks #243 out of 944 companies in the Drug Manufacturers industry, placing it in the top 25.7%.
Is Orion Oyj's 3-Year ROIIC % too high?
Orion Oyj's current 3-Year ROIIC % of 25.45 is 252% above median its 10-year median of 7.22. The Drug Manufacturers industry median 3-Year ROIIC % is 3.72. Orion Oyj's value of 25.45 is 584.1% above this industry median. Based on the distribution chart, Orion Oyj ranks #243 out of 944 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Orion Oyj has a GF Score™ of 97/100, reflecting its overall financial health beyond just this single metric.
How does Orion Oyj's 3-Year ROIIC % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Orion Oyj ranks #243 out of 944 companies for 3-Year ROIIC %. This puts Orion Oyj in the upper half of its industry. The industry median 3-Year ROIIC % is 3.72. Orion Oyj's value of 25.45 is 584.1% above this benchmark. While the company's 10-year median is 7.22 vs. the industry median of 3.72, Orion Oyj has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.72, based on 944 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orion Oyj's current 3-Year ROIIC % of 25.45 is 584.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Orion Oyj and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Oyj's current 3-Year ROIIC % is 25.45, which is 252% above median its own 10-year median of 7.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Oyj stock overvalued right now?
Orion Oyj (ORINF) has a current 3-Year ROIIC % of 25.45. The stock's GF Value™ is $80.88, compared to a current price of $82.75 — trading 2.3% above its estimated fair value. The current 3-Year ROIIC % is 25.45, which is 252% above median its 10-year median of 7.22 and 584.1% above the Drug Manufacturers industry median of 3.72. Orion Oyj's overall GF Score™ is 97/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Orion Oyj (ORINF), the current 3-Year ROIIC % is 25.45 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Oyj (ORINF) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Oyj stock appears to be overvalued.
The current stock price of $82.75 is trading 2.3% above its estimated GF Value™ of $80.88.
Key valuation signals for ORINF:
3-Year ROIIC %: 25.45 (252% above median its 10-year median of 7.22)
GF Value™: $80.88 vs. price of $82.75 (2.3% above fair value)
Industry Position: 584.1% above the Drug Manufacturers median (#243 of 944)
No single metric tells the full story. See the ORINF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Oyj is a globally operating Finnish pharmaceutical company that develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company predominantly focuses on treatments for central nervous system disorders, oncology, and respiratory diseases. Orion's customers include specialists and general practitioners, veterinarians, pharmacies, hospitals, and laboratories. The company mainly serves Finland but also has a presence in other European countries, North America and other countries.
97GF Score
Get the complete analysis for ORINF
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ORINF has been successfully added to your 
